Global Perspectives and Clinical Resources on BTK Inhibitor Therapy for Patients With CLL

In this program focused on global perspectives, get up to date on key topics in the use of BTK inhibitors for treating CLL with an expert-authored interactive text module and short commentary, downloadable slides, and Interactive Decision Support Tools for CLL and BTK inhibitor AE management.

Share

Program Content

Activities

BTKis for CLL: Module
BTK Inhibitor Therapy for Patients With CLL: A Global Perspective
Text Module
Congratulations: You achieved a completion on 04/09/2022

Released: March 13, 2023

Expires: March 12, 2024

Activities

Global CLL Treatment Tool
Expert Guidance for the Treatment of CLL: An International Perspective
Tool
Congratulations: You achieved a completion on 04/09/2022

Released: May 01, 2023

Managing BTKi AEs Global
Interactive Tool for Managing BTK Inhibitor−Associated AEs in Hematologic Malignancies: A Global Perspective
Tool
Congratulations: You achieved a completion on 04/09/2022

Released: August 15, 2023

Activities

BTKis for CLL
BTK Inhibitor Therapy for CLL: An International Perspective
Clinical Thought
Congratulations: You achieved a completion on 04/09/2022

Released: March 28, 2023

Expires: March 27, 2024

Faculty

cover img faculity

Florence Cymbalista, MD, PhD

Professor of Hematology
Sorbonne Paris Nord University
Bobigny, France

cover img faculity

Toby Eyre, MBChB, MD

Honorary Senior Lecturer
Hematology and Cancer
University of Oxford
Consultant Hematologist
Department of Hematology
Hematology and Cancer Centre, Oxford University Hospitals NHS Foundation Trust
Oxford, United Kingdom

cover img faculity

Arnon Kater, MD, PhD

Professor
Hematologist
Deputy Head
Department of Hematology
Amsterdam University Medical Centers
University of Amsterdam
Amsterdam, Netherlands

cover img faculity

Stephan Stilgenbauer, MD

Medical Director Comprehensive Cancer Center Ulm
Head, Early Clinical Trials Unit
Head, Division of CLL Dept. of Internal Medicine III
University Medical Center
Ulm University
Ulm, Germany

cover img faculity

Alessandra Tedeschi, MD

Director of Indolent Lymphoproliferative Disorders
Department of Hematology
Niguarda Cancer Center
Niguarda Hospital
Milan, Italy

Provided by

ProCE Banner

Provided by Clinical Care Options, LLC.

Supporters

Supported by an educational grant from AstraZeneca.

AstraZeneca